Saltar al contenido principal
-
/
Home
-
/
Jeffrey M. Conroy
Publications:
- April 30, 2024
Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
- March 20, 2024
OX40/OX40 Ligand and its Role in Precision Immune Oncology
- March 19, 2024
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
- February 5, 2024
Automated Tissue Dissection Solution to Support Comprehensive Genomic and Immune Profiling
- September 23, 2023
PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
- August 8, 2023
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
- June 12, 2023
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
- June 6, 2023
Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer
- June 6, 2023
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)
- May 26, 2023
Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study
- May 8, 2023
RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
- March 21, 2022
Cancer testis antigen burden: pan-cancer distribution and survival implications
- April 7, 2024
Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
- April 7, 2024
Landscape of TIGIT and PD-L1 co-expression in solid tumors
- February 12, 2024
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
- February 5, 2024
Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics
- February 5, 2024
Implementation of Laboratory Automation to Support Scaling of Cancer Patients Testing using OmniSeq® INSIGHT Molecular Diagnostic Test
- January 30, 2024
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
- January 13, 2024
Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
- December 11, 2023
Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
- December 11, 2023
Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
- November 17, 2023
Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
- November 17, 2023
Genomic stability of prostate cancers with homologous recombination gene alterations
- November 17, 2023
Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
- November 17, 2023
Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
- November 17, 2023
LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
- November 17, 2023
A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
- November 4, 2023
Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
- November 3, 2023
Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
- November 3, 2023
Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
- November 3, 2023
Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
- November 3, 2023
Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
- November 3, 2023
Immune microenvironment of primary versus metastatic melanoma of the brain
- November 3, 2023
Metastatic triple negative breast cancer has distinct tumor immune landscape
- November 1, 2023
Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
- September 1, 2022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
- March 1, 2022
Checkpoint coexpression landscape in gastroesophageal adenocarcinoma
- January 1, 2018
Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors
- February 14, 2024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer